Vaccine · Immune activation · developed by Sanofi
NVXC19 is an intramuscularly injected dispersion studied for immunization against COVID-19 and influenza in healthy volunteers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07890454 | Phase 3 | Immunization | Recruiting | SNY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
COVID-19 ImmunizationHealthy VolunteersImmunizationInfluenza Immunization
Updated Nov 1, 2026. Something wrong or missing? Report it on the SNY page.
See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SNY catalysts and pipeline →